NCT02499770 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 96
- units
- Participants
- groups
- description
- The 1st cohort in Part 1 received trilaciclib 200 mg/m\^2, IV once daily on Days 1 to 3 of each 21-day E/P cycle. The 2nd cohort in the Phase 1b dose-finding portion of Part 1 \& the Phase 2a expansion cohort in Part 1 received trilaciclib 240 mg/m\^2, IV once daily on Days 1 to 3 of each 21-day E/P cycle. Participants received standard E/P chemotherapy in 21-day cycles. Carboplatin dose was calculated using the Calvert formula with a target AUC = 5 (maximum 750 mg) IV on Day 1. Etoposide 100 mg/m\^2 was given IV daily on Days 1, 2, \& 3 of each 21-day cycle. Trilaciclib was only given with E/P therapy. If E/P therapy was discontinued, trilaciclib was also to be discontinued. The interval between doses of trilaciclib on successive days was not greater than 28 hours \& between the dose of trilaciclib \& the first dose of chemotherapy on a given day (etoposide or carboplatin) not greater than 4 hours.
- id
- BG000
- title
- Part 1: Dose Finding/Expansion
- description
- Eligible participants were randomized (1:1) to trilaciclib or placebo administered IV once daily on Days 1 to 3 of E/P therapy. Randomization was stratified by ECOG performance status (0 to 1 versus 2). Participants received trilaciclib 240 mg/m\^2 (recommended dose from Part 1) or placebo IV once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle. Participants received standard E/P chemotherapy in 21-day cycles. The carboplatin dose was calculated using the Calvert formula with a target AUC = 5 (maximum 750 mg) IV on Day 1, and 100 mg/m\^2 etoposide was administered IV daily on Days 1, 2, and 3 of each 21-day cycle. The interval between doses of trilaciclib/placebo on successive days was not greater than 28 hours and between the dose of trilaciclib/placebo and the first dose of chemotherapy on a given day (etoposide or carboplatin) was not greater than 4 hours.
- id
- BG001
- title
- Part 2: Trilaciclib/Placebo IV With E/P
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 37
- group Id
- BG002
- value
- 44
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 40
- group Id
- BG002
- value
- 52
- title
- >=65 years
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 96
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 31
- title
- Female
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 65
- title
- Male
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 96
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 75
- group Id
- BG002
- value
- 93
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Unknown or Not Reported
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 96
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 73
- group Id
- BG002
- value
- 89
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Unknown or Not Reported
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 96
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 39
- group Id
- BG002
- value
- 58
- title
- United States
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 38
- group Id
- BG002
- value
- 38
- title
- Non-United States
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 96
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Country
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 0.263
- value
- 1.90
- group Id
- BG001
- spread
- 0.216
- value
- 1.90
- comment
- Mean body surface area was not calculated for all participants overall.
- group Id
- BG002
- spread
- NA
- value
- NA
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 75
- group Id
- BG002
- value
- 94
- units
- Participants
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- population Description
- BSA was only available for 75 of the 77 participants in Part 2.
- title
- Body Surface Area
- unit Of Measure
- m^2
- population Description
- All participants randomized
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 96
- units
- Participants
- groups
- description
- The 1st cohort in Part 1 received trilaciclib 200 mg/m\^2, IV once daily on Days 1 to 3 of each 21-day E/P cycle. The 2nd cohort in the Phase 1b dose-finding portion of Part 1 \& the Phase 2a expansion cohort in Part 1 received trilaciclib 240 mg/m\^2, IV once daily on Days 1 to 3 of each 21-day E/P cycle. Participants received standard E/P chemotherapy in 21-day cycles. Carboplatin dose was calculated using the Calvert formula with a target AUC = 5 (maximum 750 mg) IV on Day 1. Etoposide 100 mg/m\^2 was given IV daily on Days 1, 2, \& 3 of each 21-day cycle. Trilaciclib was only given with E/P therapy. If E/P therapy was discontinued, trilaciclib was also to be discontinued. The interval between doses of trilaciclib on successive days was not greater than 28 hours \& between the dose of trilaciclib \& the first dose of chemotherapy on a given day (etoposide or carboplatin) not greater than 4 hours.
- id
- BG000
- title
- Part 1: Dose Finding/Expansion
- description
- Eligible participants were randomized (1:1) to trilaciclib or placebo administered IV once daily on Days 1 to 3 of E/P therapy. Randomization was stratified by ECOG performance status (0 to 1 versus 2). Participants received trilaciclib 240 mg/m\^2 (recommended dose from Part 1) or placebo IV once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle. Participants received standard E/P chemotherapy in 21-day cycles. The carboplatin dose was calculated using the Calvert formula with a target AUC = 5 (maximum 750 mg) IV on Day 1, and 100 mg/m\^2 etoposide was administered IV daily on Days 1, 2, and 3 of each 21-day cycle. The interval between doses of trilaciclib/placebo on successive days was not greater than 28 hours and between the dose of trilaciclib/placebo and the first dose of chemotherapy on a given day (etoposide or carboplatin) was not greater than 4 hours.
- id
- BG001
- title
- Part 2: Trilaciclib/Placebo IV With E/P
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 37
- group Id
- BG002
- value
- 44
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 40
- group Id
- BG002
- value
- 52
- title
- >=65 years
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 96
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 31
- title
- Female
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 65
- title
- Male
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 96
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 75
- group Id
- BG002
- value
- 93
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Unknown or Not Reported
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 96
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 73
- group Id
- BG002
- value
- 89
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Unknown or Not Reported
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 96
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 39
- group Id
- BG002
- value
- 58
- title
- United States
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 38
- group Id
- BG002
- value
- 38
- title
- Non-United States
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 77
- group Id
- BG002
- value
- 96
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Country
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 0.263
- value
- 1.90
- group Id
- BG001
- spread
- 0.216
- value
- 1.90
- comment
- Mean body surface area was not calculated for all participants overall.
- group Id
- BG002
- spread
- NA
- value
- NA
- denoms
- counts
- group Id
- BG000
- value
- 19
- group Id
- BG001
- value
- 75
- group Id
- BG002
- value
- 94
- units
- Participants
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- population Description
- BSA was only available for 75 of the 77 participants in Part 2.
- title
- Body Surface Area
- unit Of Measure
- m^2
- population Description
- All participants randomized
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle